New $46M grant allows the University of Oxford and Boston Children’s Hospital to lead Genetic Medicines Hub within ARIA ecosystem

by rss feed | Nov 10, 2026 | News Feeds

The University of Oxford and Boston Children’s Hospital, with collaboration from The Jackson Laboratory and N=1 Collaborative, have been selected to establish a new Genetic Medicines Hub, one of six research hubs within the Aligning Research to Impact Autism (ARIA)...

Could Ozempic and Wegovy affect unborn babies?

by rss feed | Nov 10, 2026 | News Feeds

They’re the blockbuster drugs transforming weight loss, helping millions of people to shed unwanted pounds. Read Original...

Lab Thread launches new AI tools and strengthens platform with universal AI assistant compatibility

by rss feed | Nov 10, 2026 | News Feeds

Lab Thread Ltd, a UK-based life science software company, today announced the launch of a new Model Context Protocol (MCP) server that lets scientists connect their own AI assistants directly to their laboratory data. Read Original...

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

by rss feed | Nov 10, 2026 | News Feeds

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small...

European commission approves label expansion of Pepaxti to third-line treatment

by rss feed | Nov 10, 2026 | News Feeds

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announced that the European Commission (EC) has formally approved the Type II variation application for Pepaxti (melflufen). Read Original...